Table of Contents
Journal of Cancer Research
Volume 2014 (2014), Article ID 249354, 9 pages
http://dx.doi.org/10.1155/2014/249354
Research Article

BAY 61-3606, CDKi, and Sodium Butyrate Treatments Modulate p53 Protein Level and Its Site-Specific Phosphorylation in Human Vestibular Schwannomas In Vitro

1Department of Human Genetics, NIMHANS, 2900 Hosur Road, Bangalore 560029, India
2Department of Studies in Sericulture/Life Sciences, Jnana Bharathi Campus, Bangalore University, Bangalore 560056, India
3Department of Biotechnology, Bharathiar University, Coimbatore 641046, India
4Department of Neuro Surgery, NIMHANS, Bangalore 560029, India

Received 18 August 2014; Revised 24 September 2014; Accepted 7 October 2014; Published 20 October 2014

Academic Editor: Wenrui Duan

Copyright © 2014 Rohan Mitra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Martuza and R. Eldridge, “Neurofibromatosis 2. (Bilateral acoustic neurofibromatosis),” The New England Journal of Medicine, vol. 318, no. 11, pp. 684–688, 1988. View at Publisher · View at Google Scholar · View at Scopus
  2. D. E. Brackmann and J. A. Kwartler, “A review of acoustic tumors: 1983–1988,” American Journal of Otology, vol. 11, no. 3, pp. 216–232, 1990. View at Google Scholar · View at Scopus
  3. D. Eliyahu, D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren, “Wild-type p53 can inhibit oncogene-mediated focus formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 22, pp. 8763–8767, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Finlay, P. W. Hinds, and A. J. Levine, “The p53 proto-oncogene can act as a suppressor of transformation,” Cell, vol. 57, no. 7, pp. 1083–1093, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. D. P. Lane, “Cancer: p53, guardian of the genome,” Nature, vol. 358, no. 6381, pp. 15–16, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. D. P. Lane and L. V. Crawford, “T antigen is bound to a host protein in SV40 transformed cells,” Nature, vol. 278, no. 5701, pp. 261–263, 1979. View at Publisher · View at Google Scholar · View at Scopus
  8. H. F. Horn and K. H. Vousden, “Coping with stress: multiple ways to activate p53,” Oncogene, vol. 26, no. 9, pp. 1306–1316, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Bode and Z. Dong, “Post-translational modification of p53 in tumorigenesis,” Nature Reviews Cancer, vol. 4, no. 10, pp. 793–805, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Gu and W.-G. Zhu, “Surf the post-translational modification network of p53 regulation,” International Journal of Biological Sciences, vol. 8, no. 5, pp. 672–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Vogelstein, D. Lane, and A. J. Levine, “Surfing the p53 network,” Nature, vol. 408, no. 6810, pp. 307–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Dai and W. Gu, “P53 post-translational modification: deregulated in tumorigenesis,” Trends in Molecular Medicine, vol. 16, no. 11, pp. 528–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. H. P. P. Dayalan, M. Jothi, R. Keshava et al., “Age dependent phosphorylation and deregulation of p53 in human vestibular schwannomas,” Molecular Carcinogenesis, vol. 45, no. 1, pp. 38–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Rohini, J. Mathivanan, P. D. A. H. Prabhu et al., “Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors,” Molecular and Cellular Biochemistry, vol. 300, no. 1-2, pp. 101–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. K. Bar, I. Saomska, J. Rabczyńki, L. Noga, and M. Grybov, “Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms correlation with clinicopathological parameters of tumors,” International Journal of Gynecological Cancer, vol. 19, no. 8, pp. 1322–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Piccinin, E. Tonin, S. Sessa et al., “A “twist box” code of p53 inactivation: twist box: p53 interaction promotes p53 degradation,” Cancer Cell, vol. 22, no. 3, pp. 404–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. Blaydes, M. G. Luciani, S. Pospisilova, H. M.-L. Ball, B. Vojtesek, and T. R. Hupp, “Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription,” The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4699–4708, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Malumbres and M. Barbacid, “Cell cycle, CDKs and cancer: a changing paradigm,” Nature Reviews Cancer, vol. 9, no. 3, pp. 153–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Sada, T. Takano, S. Yanagi, and H. Yamamura, “Structure and function of syk protein-tyrosine kinase,” The Journal of Biochemistry, vol. 130, no. 2, pp. 177–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Yanagi, R. Inatome, T. Takano, and H. Yamamura, “Syk expression and novel function in a wide variety of tissues,” Biochemical and Biophysical Research Communications, vol. 288, no. 3, pp. 495–498, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Yamamoto, K. Takeshita, M. Shichijo et al., “The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents,” The Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 1174–1181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Gope and M. L. Gope, “Effect of sodium butyrate on the expression of retinoblastoma (RB1) and P53 gene and phosphorylation of retinoblastoma protein in human colon tumor cell line HT29,” Cellular and Molecular Biology, vol. 39, no. 6, pp. 589–597, 1993. View at Google Scholar · View at Scopus
  23. A. Rephaeli, E. Rabizadeh, A. Aviram, M. Shaklai, M. Ruse, and A. Nudelman, “Derivatives of butyric acid as potential anti-neoplastic agents,” International Journal of Cancer, vol. 49, no. 1, pp. 66–72, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. J. R. Davie, “Inhibition of histone deacetylase activity by butyrate,” The Journal of Nutrition, vol. 133, no. 7, pp. 2485S–2493S, 2003. View at Google Scholar · View at Scopus
  25. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. W. DePinto, X.-J. Chu, M. Smith et al., “In vitro and in vivo activity of R547: a potent selective cyclin-dependent kinase inhibitor currently in phase I clinical trials,” Molecular Cancer Therapeutics, vol. 5, no. 11, pp. 2644–2658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Mitra, B. I. Devi, M. L. Gope, D. K. Subbakrishna, and R. Gope, “Sodium butyrate modulates pRb phosphorylation and induces cell death in human vestibular schwannomas in vitro,” Indian Journal of Experimental Biology, vol. 50, no. 1, pp. 19–27, 2012. View at Google Scholar · View at Scopus
  28. R. Mitra, I. D. Bhagavatula, and R. Gope, “BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro,” ecancermedicalscience, vol. 6, no. 1, article 285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Gope and M. L. Gope, “Abundance and state of phosphorylation of the retinoblastoma susceptibility gene product in human colon cancer,” Molecular and Cellular Biochemistry, vol. 110, no. 2, pp. 123–133, 1992. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Matsumoto, M. Furihata, A. Kurabayashi, and Y. Ohtsuki, “Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors,” Oncology Reports, vol. 12, no. 5, pp. 1039–1043, 2004. View at Google Scholar · View at Scopus
  31. M. Matsumoto, M. Furihata, A. Kurabayashi et al., “Prognostic signifi cance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma,” Oncology, vol. 67, no. 2, pp. 143–150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, “Mdm2 promotes the rapid degradation of p53,” Nature, vol. 387, no. 6630, pp. 296–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. M. H. G. Kubbutat, S. N. Jones, and K. H. Vousden, “Regulation of p53 stability by Mdm2,” Nature, vol. 387, no. 6630, pp. 299–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine, “The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation,” Cell, vol. 69, no. 7, pp. 1237–1245, 1992. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Toledo and G. M. Wahl, “Regulating the p53 pathway: in vitro hypotheses, in vivo veritas,” Nature Reviews Cancer, vol. 6, no. 12, pp. 909–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Huang, L. Perez-Burgos, B. J. Placek et al., “Repression of p53 activity by Smyd2-mediated methylation,” Nature, vol. 444, no. 7119, pp. 629–632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Sakaguchi, H. Sakamoto, M. S. Lewis et al., “Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53,” Biochemistry, vol. 36, no. 33, pp. 10117–10124, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Fogal, J.-K. Hsieh, C. Royer, S. Zhong, and X. Lu, “Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315,” The EMBO Journal, vol. 24, no. 15, pp. 2768–2782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Katayama, K. Sasai, H. Kawai et al., “Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53,” Nature Genetics, vol. 36, no. 1, pp. 55–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. H.-H. Li, X. Cai, G. P. Shouse, L. G. Piluso, and X. Liu, “A specific PP2A regulatory subunit, B56γ, mediates DNA damage-induced dephosphorylation of p53 at Thr55,” The EMBO Journal, vol. 26, no. 2, pp. 402–411, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Saito, H. Yamaguchi, Y. Higashimoto et al., “Phosphorylation site interdependence of human p53 post-translational modifications in response to stress,” The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37536–37544, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Chopin, R.-A. Toillon, N. Jouy, and X. Le Bourhis, “Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells,” British Journal of Pharmacology, vol. 135, no. 1, pp. 79–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Mawrin, E. Kirches, K. Dietzmann, A. Roessner, and C. Boltze, “Expression pattern of apoptotic markers in vestibular schwannomas,” Pathology Research and Practice, vol. 198, no. 12, pp. 813–819, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. T. D. Halazonetis, L. J. Davis, and A. N. Kandil, “Wild-type p53 adopts a “mutant”-like conformation when bound to DNA,” The EMBO Journal, vol. 12, no. 3, pp. 1021–1028, 1993. View at Google Scholar · View at Scopus
  45. T. Minamoto, T. Buschmann, H. Habelhah et al., “Distinct pattern of p53 phosphorylation in human tumors,” Oncogene, vol. 20, no. 26, pp. 3341–3347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Peng, C. Li, L. Chen, S. Sebti, and J. Chen, “Rescue of mutant p53 transcription function by ellipticine,” Oncogene, vol. 22, no. 29, pp. 4478–4487, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Ishimaru, L. F. Maia, L. M. Maiolino et al., “Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant,” Journal of Molecular Biology, vol. 333, no. 2, pp. 443–451, 2003. View at Publisher · View at Google Scholar · View at Scopus